- Home
- VOXR vs ALDX Comparison
VOXR vs ALDX Comparison
Compare VOXR & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VOXR | ALDX |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.5M | 317.7M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | VOXR | ALDX |
|---|---|---|
| Price | $5.58 | $4.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 484.4K | ★ 1.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.88% | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.87 | N/A |
| Revenue Next Year | $90.76 | $123.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.58 | $1.18 |
| 52 Week High | $6.59 | $6.99 |
Technical Indicators
Market Signals| Indicator | VOXR | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 45.57 | 34.77 |
| Support Level | $4.76 | $2.60 |
| Resistance Level | $5.88 | $5.70 |
| Average True Range (ATR) | 0.36 | 0.43 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 17.74 | 6.36 |
Price Performance
Historical ComparisonAbout VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.